We talk to Vellalore Kakkanaiah about his work using flow cytometry in adoptive cell therapy in this interview as part of our author’s perspective series.
Join us for our Twitter chat with proteomics experts on Friday 22nd February at 15:00 [GMT], 10:00 [EST], where we will discuss the applications of proteomics, mass spectrometry techniques and the challenges of proteomics research #TalkProteomics.
This editorial provides an insight into the advancing field of microsampling as a tool to monitor critically ill patients in the clinic, highlighting the need for further development to ensure patients receive the highest quality of care.
In this Bioanalysis Zone interview, Pegah Jalili (MilliporeSigma) discusses her current work in analytical R&D of biotherapeutic characterization and quantification, and what she thinks the future looks like for this field of bioanalysis.
An author’s perspective: Zhengqi Ye on approaches to measure protein binding of enzymatically unstable compounds
We talk to Zhengqi Ye about the approaches she uses to measure protein binding of enzymatically unstable compounds in plasma in this interview as part of our author’s perspective series.
We talk to Laura Rowe about her work using UHPLC to analyse protein glycosylation in this interview as part of our author’s perspective series.
In this interview, Laura Mercolini (University of Bologna) discusses the advantages and disadvantages of using volumetric absorptive microsampling (VAMS) as a bioanalytical tool, touching upon her recent paper on the same topic.
This editorial provides an insight into the development of proteomics as a tool for drug and biomarker discovery, pharmacodynamics and protein network elucidation; and where technology may be heading in the future.
An author’s perspective: Wenying Jian on bioanalytical workflow for novel scaffold protein–drug conjugates
We talk to Wenying Jian about her work on the quantitation of total Centyrin protein using liquid chromatography–tandem mass spectrometry in this interview as part of our author’s perspective series.
Mike Brown (Q-Squared Solutions; GA, USA), discusses the different tests required when looking at a potential therapeutic and what aspects of biology need to be considered. He also explores how important early engagement with the FDA and clinical trial partners are.